CAH

+ Watchlist + Portfolio

Cardinal Health, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $234.85
52-Week Range: $145.87 – $258.30
Market Cap: $53.13B
P/E (TTM): 31.60
EPS (TTM): 7.23
Dividend Yield: 0.88%

Advanced Metrics

Price/Book: —
PEG Ratio: 1.20
Return on Equity: —
Return on Assets: 3.72%
Gross Margin: 3.84%
Operating Margin: 1.33%
Profit Margin: 0.67%
Current Ratio: 0.88
Debt/Equity: —
Total Debt: $10.00B
Free Cash Flow: $4.75B
Revenue Growth: 5.80%
Earnings Growth: 68.80%
Enterprise Value: $59.92B

CAH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$181.33B	$204.98B	$226.83B	$222.58B
Cost of Revenue	$174.84B	$198.10B	$219.41B	$214.41B
Gross Profit	$6.48B	$6.87B	$7.41B	$8.17B
Selling, General & Admin	$4.51B	$4.80B	$5.00B	$5.38B
Operating Expenses	$4.84B	$5.08B	$5.28B	$5.85B
Operating Income	$1.65B	$1.79B	$2.13B	$2.32B
EBITDA	$55.00M	$1.44B	$1.96B	$3.11B
Pretax Income	-$784.00M	$663.00M	$1.20B	$2.10B
Income Tax	$153.00M	$332.00M	$348.00M	$532.00M
Net Income	-$938.00M	$330.00M	$852.00M	$1.56B
Diluted EPS	-3.35	1.00	3.45	6.45
Diluted Shares	279.00M	262.00M	247.00M	242.00M

CAH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.72B	$4.08B	$5.13B	$3.87B
Receivables	$10.56B	$11.11B	$12.08B	$13.24B
Inventory	$15.64B	$16.12B	$14.96B	$16.83B
Current Assets	$32.94B	$33.74B	$34.88B	$36.37B
Total Assets	$43.88B	$43.35B	$45.12B	$53.12B
Current Liabilities	$30.55B	$33.74B	$35.64B	$38.90B
Long-Term Debt	$4.74B	$3.91B	$4.66B	$7.98B
Total Debt	$5.32B	$4.70B	$5.09B	$8.53B
Total Liabilities	$44.58B	$46.31B	$48.33B	$55.76B
Retained Earnings	-$280.00M	-$642.00M	-$286.00M	$783.00M
Shareholders' Equity	-$709.00M	-$2.96B	-$3.21B	-$2.78B
Working Capital	$2.38B	-$3.00M	-$756.00M	-$2.52B
Net Debt	$598.00M	$625.00M	—	$4.65B

CAH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$3.17B	$2.84B	$3.76B	$2.40B
Capital Expenditure	-$387.00M	-$481.00M	-$511.00M	-$547.00M
Free Cash Flow	$2.79B	$2.36B	$3.25B	$1.85B
Depreciation & Amortisation	$692.00M	$692.00M	$710.00M	$790.00M
Stock-Based Compensation	$81.00M	$96.00M	$121.00M	$244.00M
Investing Cash Flow	$567.00M	-$454.00M	-$1.85B	-$5.59B
Financing Cash Flow	-$2.46B	-$3.05B	-$847.00M	$1.94B
Dividends Paid	-$559.00M	-$525.00M	-$499.00M	-$494.00M
Share Repurchases	-$1.00B	-$2.00B	-$750.00M	-$765.00M
Net Change in Cash	$1.28B	-$661.00M	$1.07B	-$1.26B

CAH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$54.88B	$60.16B	$64.01B	$65.63B	$60.94B
Cost of Revenue	$52.76B	$57.96B	$61.69B	$63.23B	$58.44B
Gross Profit	$2.12B	$2.20B	$2.32B	$2.40B	$2.50B
Selling, General & Admin	$1.31B	$1.48B	$1.46B	$1.50B	$1.54B
Operating Expenses	$1.47B	$1.62B	$1.56B	$1.63B	$1.66B
Operating Income	$656.00M	$585.00M	$754.00M	$763.00M	$842.00M
EBITDA	$946.00M	$667.00M	$911.00M	$952.00M	$741.00M
Pretax Income	$665.00M	$384.00M	$598.00M	$630.00M	$392.00M
Income Tax	$157.00M	$141.00M	$144.00M	$159.00M	$12.00M
Net Income	$506.00M	$239.00M	$450.00M	$467.00M	$399.00M
Diluted EPS	2.10	1.00	1.88	1.97	1.69
Diluted Shares	241.00M	240.00M	239.00M	237.00M	236.00M

CAH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.33B	$3.87B	$4.59B	$2.78B	$3.94B
Receivables	$12.67B	$13.24B	$13.77B	$13.66B	$13.65B
Inventory	$16.16B	$16.83B	$17.56B	$20.12B	$18.01B
Current Assets	$34.59B	$36.37B	$38.54B	$39.23B	$38.06B
Total Assets	$49.87B	$53.12B	$55.23B	$58.08B	$56.69B
Current Liabilities	$36.66B	$38.90B	$40.27B	$43.31B	$41.99B
Long-Term Debt	$7.14B	$7.98B	$8.98B	$8.35B	$8.24B
Total Debt	$7.68B	$8.53B	$9.03B	$9.03B	$8.92B
Total Liabilities	$51.77B	$55.76B	$57.96B	$60.78B	$59.36B
Retained Earnings	$664.00M	$783.00M	$1.12B	$1.46B	$1.73B
Shareholders' Equity	-$2.95B	-$2.78B	-$2.88B	-$2.88B	-$2.83B
Working Capital	-$2.07B	-$2.52B	-$1.73B	-$4.08B	-$3.92B
Net Debt	$4.35B	$4.65B	$4.44B	$6.25B	$4.98B

CAH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$2.92B	$1.53B	$973.00M	$686.00M	$1.82B
Capital Expenditure	-$126.00M	-$232.00M	-$108.00M	-$131.00M	-$146.00M
Free Cash Flow	$2.79B	$1.29B	$865.00M	$555.00M	$1.68B
Depreciation & Amortisation	$207.00M	$209.00M	$233.00M	$234.00M	$248.00M
Stock-Based Compensation	$31.00M	$153.00M	$93.00M	$87.00M	$129.00M
Investing Cash Flow	-$2.90B	-$1.63B	-$142.00M	-$1.98B	-$181.00M
Financing Cash Flow	-$510.00M	$656.00M	-$110.00M	-$519.00M	-$483.00M
Dividends Paid	-$124.00M	-$120.00M	-$129.00M	-$122.00M	-$120.00M
Share Repurchases	-$375.00M	$0.00	-$375.00M	-$383.00M	-$250.00M
Net Change in Cash	-$488.00M	$552.00M	$721.00M	-$1.81B	$1.16B

Market Snapshot

About

Cardinal Health, Inc. is a global healthcare services and products company providing pharmaceuticals, medical products, and solutions to hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two primary segments: Pharmaceutical (pharmaceutical distribution and specialty solutions) and Medical (medical and laboratory products distribution and manufacturing). Cardinal Health distributes branded and generic pharmaceuticals to retail pharmacies, hospitals, and other healthcare providers, representing a critical link in pharmaceutical supply chains. The company also distributes medical-surgical supplies, operates pharmacy management services, and manufactures medical products including surgical gloves and gowns. Founded in 1971 and headquartered in Dublin, Ohio, Cardinal Health is one of the three dominant U.S. pharmaceutical distributors alongside McKesson and AmerisourceBergen. The company operates on thin margins in distribution businesses but generates stable cash flows from essential services. Cardinal Health faces opioid litigation and settlements, generic drug pricing pressures, customer concentration risks, and competition. The company continues to focus on specialty pharmaceuticals, at-home care solutions, and operational efficiency.